NASDAQ:NXTM - NxStage Stock Price, Price Target & More

$25.50 +0.09 (+0.35 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$25.41
Today's Range$25.32 - $25.72
52-Week Range$20.45 - $30.80
Volume149,762 shs
Average Volume569,755 shs
Market Capitalization$1.72 billion
P/E Ratio-115.91
Dividend YieldN/A
Beta-0.01

About NxStage (NASDAQ:NXTM)

NxStage logoNxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.23%
Quick Ratio2.20%

Price-To-Earnings

Trailing P/E Ratio-115.91
Forward P/E Ratio425.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$393.94 million
Price / Sales4.29
Cash Flow$0.2870 per share
Price / Cash88.85
Book Value$3.22 per share
Price / Book7.92

Profitability

EPS (Most Recent Fiscal Year)($0.22)
Net Income$-14,470,000.00
Net Margins-3.68%
Return on Equity-6.80%
Return on Assets-4.45%

Miscellaneous

Employees3,800
Outstanding Shares66,320,000

How to Become a New Pot Stock Millionaire

NxStage (NASDAQ:NXTM) Frequently Asked Questions

What is NxStage's stock symbol?

NxStage trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage's earnings last quarter?

NxStage (NASDAQ:NXTM) issued its quarterly earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage had a negative return on equity of 6.80% and a negative net margin of 3.68%. NxStage's revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.03) EPS. View NxStage's Earnings History.

What price target have analysts set for NXTM?

8 brokers have issued 1 year target prices for NxStage's stock. Their predictions range from $27.00 to $32.00. On average, they anticipate NxStage's share price to reach $29.8571 in the next year. View Analyst Ratings for NxStage.

What are Wall Street analysts saying about NxStage stock?

Here are some recent quotes from research analysts about NxStage stock:
  • 1. According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (3/7/2018)
  • 2. Northland Securities analysts commented, "We continue to move our PD program forward at an impressive pace…We continue to firmly believe that by keeping our regulatory timelines and pathway confidential, we’re protecting a significant value opportunity. Let me be clear, we both have the opportunity to do great things for patients, bringing new technology to the market that makes PD easier and better." (8/7/2017)

Who are some of NxStage's key competitors?

Who are NxStage's key executives?

NxStage's management team includes the folowing people:
  • Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 55)
  • Mr. Joseph E. Turk Jr., Pres (Age 50)
  • Mr. Matthew W. Towse, Sr. VP, CFO, Principal Accounting Officer & Treasurer (Age 55)
  • Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Dr. Allan J. Collins M.D., FACP, Head of Scientific Advisory Board and Chief Medical Officer

Has NxStage been receiving favorable news coverage?

Headlines about NXTM stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NxStage earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the medical device company an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of NxStage?

Shares of NXTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage's stock price today?

One share of NXTM stock can currently be purchased for approximately $25.50.

How big of a company is NxStage?

NxStage has a market capitalization of $1.72 billion and generates $393.94 million in revenue each year. The medical device company earns $-14,470,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. NxStage employs 3,800 workers across the globe.

How can I contact NxStage?

NxStage's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage (NXTM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about NxStage and other stocks. Vote "Outperform" if you believe NXTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NxStage (NASDAQ:NXTM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for NxStage in the last 12 months. Their average twelve-month price target is $29.8571, suggesting that the stock has a possible upside of 17.09%. The high price target for NXTM is $32.00 and the low price target for NXTM is $27.00. There are currently 8 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.8571$29.8571$29.8571$29.8571
Price Target Upside: 17.09% upside15.48% upside15.48% upside7.63% upside

NxStage (NASDAQ:NXTM) Consensus Price Target History

Price Target History for NxStage (NASDAQ:NXTM)

NxStage (NASDAQ:NXTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Northland SecuritiesReiterated RatingHold$30.00N/AView Rating Details
10/17/2017Canaccord GenuityReiterated RatingHold$30.00N/AView Rating Details
8/22/2017Leerink SwannDowngradeOutperform -> Market Perform$28.00 -> $30.00HighView Rating Details
8/11/2017BTIG ResearchDowngradeBuy -> NeutralLowView Rating Details
8/9/2017StephensDowngradeOverweight -> Equal Weight$33.00 -> $30.00LowView Rating Details
8/8/2017Jefferies GroupDowngradeBuy -> Hold$33.00 -> $30.00MediumView Rating Details
8/7/2017William BlairDowngradeOutperform -> Market PerformMediumView Rating Details
8/7/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
6/3/2016Piper JaffrayReiterated RatingBuy$21.00N/AView Rating Details
5/5/2016Wells FargoReiterated RatingSellN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

NxStage (NASDAQ:NXTM) Earnings History and Estimates Chart

Earnings by Quarter for NxStage (NASDAQ:NXTM)

NxStage (NASDAQ:NXTM) Earnings Estimates

2018 EPS Consensus Estimate: $0.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.01$0.02$0.02
Q2 20182$0.01$0.01$0.01
Q3 20182$0.02$0.05$0.04
Q4 20182$0.04$0.05$0.05

NxStage (NASDAQ NXTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.0260)($0.03)$96.47 million$92.20 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.03)($0.02)$95.31 million$96.83 millionViewListenView Earnings Details
2/28/2017Q416($0.02)($0.02)$91.82 million$93.01 millionViewListenView Earnings Details
8/4/2016Q216($0.04)($0.03)$89.44 million$92.20 millionViewN/AView Earnings Details
5/4/2016Q116($0.05)($0.02)$88.40 million$89.20 millionViewListenView Earnings Details
2/10/2016Q415($0.04)($0.04)$86.83 million$89.80 millionViewListenView Earnings Details
11/3/2015Q315($0.08)($0.03)$82.06 million$86.50 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.08)$79.89 million$80.30 millionViewListenView Earnings Details
5/6/2015Q115($0.11)($0.09)$77.92 million$79.50 millionViewListenView Earnings Details
2/26/2015Q414($0.10)($0.08)$75.75 million$79.90 millionViewListenView Earnings Details
11/6/2014Q3($0.13)($0.07)$71.83 million$75.30 millionViewN/AView Earnings Details
8/7/2014Q214($0.11)($0.12)$70.52 million$74.10 millionViewN/AView Earnings Details
5/8/2014Q114($0.11)($0.09)$69.44 million$72.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.08)$67.66 million$69.40 millionViewN/AView Earnings Details
11/7/2013Q313$0.22($0.08)$124.03 million$66.90 millionViewListenView Earnings Details
7/25/2013Q2 2013($0.07)($0.06)$64.66 million$65.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.08)($0.08)$61.14 million$61.60 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.05)($0.04)$63.54 million$65.00 millionViewN/AView Earnings Details
11/8/2012Q312($0.06)($0.04)$60.90 million$61.00 millionViewN/AView Earnings Details
8/8/2012($0.09)($0.09)ViewN/AView Earnings Details
5/8/2012($0.09)($0.09)ViewN/AView Earnings Details
2/29/2012($0.09)($0.08)ViewN/AView Earnings Details
11/3/2011($0.10)($0.10)ViewN/AView Earnings Details
8/3/2011($0.10)($0.10)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.12)($0.11)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.14)($0.13)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.16)($0.17)ViewN/AView Earnings Details
7/23/2010Q2 2010($0.18)($0.17)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.20)($0.19)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.23)($0.22)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.26)($0.27)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.28)($0.26)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.28)($0.26)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.32)($0.29)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.34)($0.32)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.39)($0.38)ViewN/AView Earnings Details
2/12/2008Q4 2007($0.33)($0.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NxStage (NASDAQ:NXTM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NxStage (NASDAQ NXTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 84.14%
Insider Trading History for NxStage (NASDAQ:NXTM)
Insider Trading History for NxStage (NASDAQ:NXTM)

NxStage (NASDAQ NXTM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Winifred L SwanSVPSell3,500$24.48$85,680.00View SEC Filing  
1/16/2018Winifred L SwanSVPSell3,500$24.88$87,080.0013,770View SEC Filing  
12/20/2017Winifred L SwanSVPSell3,500$25.35$88,725.0014,270View SEC Filing  
11/15/2017Winifred L SwanSVPSell3,500$25.73$90,055.00View SEC Filing  
10/20/2017Winifred L SwanSVPSell3,500$27.50$96,250.0015,270View SEC Filing  
10/4/2017Joseph E Turk JrPresidentSell1,000$27.56$27,560.00View SEC Filing  
9/20/2017Matthew W TowseSVPSell4,300$27.27$117,261.0028,721View SEC Filing  
9/5/2017Joseph E Turk JrPresidentSell1,000$27.95$27,950.0073,903View SEC Filing  
8/21/2017Matthew W TowseSVPSell4,300$29.22$125,646.0028,721View SEC Filing  
8/15/2017Winifred L SwanSVPSell3,500$29.21$102,235.0016,270View SEC Filing  
8/10/2017Joseph E Turk JrPresidentSell1,000$29.26$29,260.0074,903View SEC Filing  
8/7/2017Joseph E Turk JrPresidentSell24,000$29.64$711,360.0082,903View SEC Filing  
8/3/2017Joseph E Turk JrPresidentSell7,000$22.98$160,860.0082,903View SEC Filing  
7/20/2017Matthew W TowseSVPSell4,300$24.16$103,888.0028,721View SEC Filing  
7/5/2017Joseph E Turk JrPresidentSell1,000$25.19$25,190.0075,903View SEC Filing  
6/20/2017Matthew W TowseSVPSell4,300$23.29$100,147.0029,637View SEC Filing  
6/15/2017Winifred L SwanSVPSell3,500$23.14$80,990.0017,270View SEC Filing  
6/14/2017Joseph E Turk JrPresidentSell1,000$23.74$23,740.0075,903View SEC Filing  
5/22/2017Matthew W TowseSVPSell4,300$21.36$91,848.0029,637View SEC Filing  
5/15/2017Winifred L SwanSVPSell3,500$21.94$76,790.0017,770View SEC Filing  
5/10/2017Joseph E Turk JrPresidentSell250$23.59$5,897.5078,153View SEC Filing  
5/3/2017Joseph E Turk JrPresidentSell1,000$29.95$29,950.0077,903View SEC Filing  
4/20/2017Jeffrey H BurbankCEOSell3,000$27.28$81,840.00939,086View SEC Filing  
4/20/2017Matthew W TowseSVPSell4,300$27.28$117,304.0029,637View SEC Filing  
4/19/2017Jeffrey H BurbankCEOSell3,000$26.65$79,950.00942,086View SEC Filing  
4/13/2017Joseph E Turk JrPresidentSell1,000$26.10$26,100.0078,903View SEC Filing  
4/3/2017Robert S BrownInsiderSell14,397$26.60$382,960.2028,003View SEC Filing  
3/22/2017Jeffrey H BurbankCEOSell3,000$27.42$82,260.00945,086View SEC Filing  
3/21/2017Jeffrey H BurbankCEOSell3,000$27.72$83,160.00948,086View SEC Filing  
3/20/2017Winifred L SwanSVPSell15,723$27.66$434,898.1830,993View SEC Filing  
3/16/2017Craig W MooreDirectorSell1,000$27.93$27,930.0094,943View SEC Filing  
3/8/2017Joseph E Turk JrPresidentSell1,000$27.53$27,530.0079,903View SEC Filing  
3/7/2017Robert S BrownInsiderSell20,000$27.75$555,000.0036,086View SEC Filing  
3/6/2017Robert S BrownInsiderSell6,390$28.01$178,983.9027,062View SEC Filing  
2/23/2017Jeffrey H BurbankCEOSell7,500$28.97$217,275.00936,249View SEC Filing  
2/22/2017Jeffrey H BurbankCEOSell7,500$29.01$217,575.00943,749View SEC Filing  
2/17/2017Joseph E Turk JrPresidentSell6,000$29.66$177,960.0075,280View SEC Filing  
2/15/2017Winifred L SwanSVPSell16,049$28.01$449,532.4926,522View SEC Filing  
2/14/2017Robert S BrownInsiderSell2,448$28.28$69,229.4417,315View SEC Filing  
2/10/2017Joseph E Turk JrPresidentSell3,500$28.36$99,260.0069,280View SEC Filing  
2/8/2017Robert S BrownInsiderSell3,054$27.61$84,320.9419,763View SEC Filing  
2/7/2017Robert S BrownInsiderSell3,117$27.54$85,842.1822,817View SEC Filing  
2/6/2017Robert S BrownInsiderSell16,283$26.87$437,524.2142,217View SEC Filing  
2/2/2017Joseph E Turk JrPresidentSell15,669$26.19$410,371.1172,949View SEC Filing  
2/2/2017Robert S BrownInsiderSell37,347$26.68$996,417.9653,564View SEC Filing  
1/26/2017Robert S BrownInsiderSell42,000$26.05$1,094,100.0055,564View SEC Filing  
1/23/2017Robert S BrownInsiderSell21,615$26.20$566,313.0040,764View SEC Filing  
1/20/2017Matthew W TowseSVPSell4,300$26.19$112,617.0023,041View SEC Filing  
1/18/2017Jeffrey H BurbankCEOSell7,500$27.63$207,225.00867,616View SEC Filing  
1/18/2017Robert S BrownInsiderSell8,183$27.58$225,687.1447,179View SEC Filing  
1/17/2017Jeffrey H BurbankCEOSell7,500$27.52$206,400.00875,116View SEC Filing  
1/17/2017Robert S BrownInsiderSell10,805$27.72$299,514.6055,362View SEC Filing  
1/13/2017Joseph E Turk JrPresidentSell7,500$28.00$210,000.0070,280View SEC Filing  
1/11/2017Joseph E Turk JrPresidentSell1,000$27.77$27,770.0077,780View SEC Filing  
12/20/2016Matthew W TowseSVPSell4,300$25.55$109,865.0023,041View SEC Filing  
12/15/2016Winifred L SwanSVPSell3,500$25.91$90,685.0014,973View SEC Filing  
12/14/2016Jeffrey H BurbankCEOSell7,500$25.68$192,600.00882,616View SEC Filing  
12/13/2016Jeffrey H BurbankCEOSell7,500$25.42$190,650.00890,116View SEC Filing  
12/13/2016Joseph E Turk JrPresidentSell1,000$25.42$25,420.0078,780View SEC Filing  
11/28/2016Joseph E Turk JrPresidentSell12,169$26.01$316,515.6986,780View SEC Filing  
11/23/2016Jeffrey H BurbankCEOSell7,500$24.01$180,075.00897,616View SEC Filing  
11/22/2016Jeffrey H BurbankCEOSell7,500$25.51$191,325.00905,116View SEC Filing  
11/22/2016Winifred L SwanSVPSell3,000$25.51$76,530.0014,973View SEC Filing  
11/21/2016Daniel A GianniniDirectorSell6,449$25.96$167,416.0463,193View SEC Filing  
11/21/2016Matthew W TowseSVPSell4,300$26.23$112,789.0023,041View SEC Filing  
11/17/2016Joseph E Turk JrPresidentSell1,000$25.97$25,970.0079,780View SEC Filing  
11/16/2016Joseph E Turk JrPresidentSell22,500$26.26$590,850.0080,780View SEC Filing  
9/14/2016Craig W MooreDirectorSell3,000$23.31$69,930.0090,739View SEC Filing  
5/12/2016Joseph E Turk JrPresidentSell1,500$17.89$26,835.00103,280View SEC Filing  
5/10/2016Joseph E Turk JrPresidentSell1,057$18.00$19,026.00105,837View SEC Filing  
4/21/2016Joseph E Turk JrPresidentSell2,000$15.73$31,460.00104,780View SEC Filing  
4/14/2016Winifred L SwanSVPSell6,260$16.40$102,664.0015,734View SEC Filing  
4/5/2016Joseph E Turk JrPresidentSell2,500$15.05$37,625.00109,280View SEC Filing  
3/22/2016Joseph E Turk JrPresidentSell2,000$14.34$28,680.00108,280View SEC Filing  
3/14/2016Winifred L SwanSVPSell620$15.69$9,727.8018,234View SEC Filing  
3/10/2016Joseph E Turk JrPresidentSell2,500$15.58$38,950.00112,780View SEC Filing  
2/24/2016Barry M StraubeDirectorBuy1,500$14.20$21,300.001,500View SEC Filing  
2/24/2016Joseph E Turk JrPresidentSell2,992$14.12$42,247.04108,155View SEC Filing  
2/16/2016Winifred L. SwanSVPSell2,500$14.07$35,175.0012,439View SEC Filing  
2/12/2016Earl R. LewisDirectorBuy21,000$14.63$307,230.0088,145View SEC Filing  
2/10/2016Joseph E. Turk, Jr.PresidentSell991$16.25$16,103.75107,163View SEC Filing  
2/9/2016Joseph E. Turk, Jr.PresidentSell2,500$16.88$42,200.00107,163View SEC Filing  
2/4/2016Joseph E. Turk, Jr.PresidentSell991$19.60$19,423.60108,663View SEC Filing  
1/20/2016Joseph E Turk JrPresidentSell2,000$18.75$37,500.00108,663View SEC Filing  
1/14/2016Winifred L. SwanSVPSell620$19.04$11,804.8014,319View SEC Filing  
1/11/2016Matthew W. TowseSVPSell3,472$20.40$70,828.8012,947View SEC Filing  
1/8/2016Joseph E. Turk, Jr.PresidentSell1,500$21.03$31,545.00110,663View SEC Filing  
1/7/2016Joseph E. Turk, Jr.PresidentSell3,713$20.78$77,156.14110,663View SEC Filing  
12/22/2015Joseph E. Turk, Jr.PresidentSell5,000$20.92$104,600.00100,963View SEC Filing  
12/16/2015Joseph E. Turk, Jr.PresidentSell800$19.99$15,992.00102,963View SEC Filing  
12/15/2015Matthew W. TowseSVPSell2,863$19.51$55,857.1312,947View SEC Filing  
12/14/2015Winifred L. SwanSVPSell2,500$18.90$47,250.0014,319View SEC Filing  
12/10/2015Jeffrey H. BurbankCEOSell9,274$18.94$175,649.56876,756View SEC Filing  
12/8/2015Joseph E. Turk, Jr.PresidentSell2,913$19.38$56,453.94102,963View SEC Filing  
11/20/2015Craig W MooreDirectorSell1,000$20.00$20,000.0092,046View SEC Filing  
11/19/2015Joseph E Turk JrPresidentSell2,000$19.65$39,300.00104,463View SEC Filing  
11/18/2015Craig W MooreDirectorSell4,000$19.60$78,400.0093,046View SEC Filing  
11/16/2015Winifred L. SwanSVPSell2,500$19.65$49,125.0016,199View SEC Filing  
11/12/2015Joseph E. Turk, Jr.PresidentSell4,055$20.44$82,884.20106,463View SEC Filing  
11/10/2015Jeffrey H. BurbankCEOSell10,000$20.75$207,500.00876,756View SEC Filing  
11/10/2015Joseph E. Turk, Jr.PresidentSell7,500$21.03$157,725.00107,963View SEC Filing  
11/10/2015Matthew W. TowseSVPSell2,863$20.32$58,176.1612,947View SEC Filing  
11/9/2015Daniel A GianniniDirectorSell6,593$20.30$133,837.9063,780View SEC Filing  
11/9/2015Jeffrey H. BurbankCEOSell10,000$20.32$203,200.00876,756View SEC Filing  
11/4/2015Joseph E. Turk, Jr.PresidentSell4,826$19.62$94,686.12107,963View SEC Filing  
11/4/2015Matthew W. TowseSVPSell8,591$19.50$167,524.5012,947View SEC Filing  
11/3/2015Robert S. BrowninsiderSell44,400$19.00$843,600.0059,777View SEC Filing  
10/20/2015Joseph E. Turk, Jr.PresidentSell2,000$15.80$31,600.00107,963View SEC Filing  
10/16/2015Jeffrey H. BurbankCEOSell10,000$15.59$155,900.00876,756View SEC Filing  
10/15/2015Jeffrey H. BurbankCEOSell10,000$14.98$149,800.00876,756View SEC Filing  
10/14/2015Winifred L. SwanSVPSell2,500$15.46$38,650.0018,079View SEC Filing  
10/8/2015Joseph E. Turk, Jr.PresidentSell2,839$15.42$43,777.38104,163View SEC Filing  
9/24/2015Joseph E Turk JrPresidentSell2,000$17.26$34,520.00105,663View SEC Filing  
9/17/2015Jeffrey H. BurbankCEOSell10,000$16.18$161,800.00876,756View SEC Filing  
9/16/2015Jeffrey H. BurbankCEOSell10,000$15.99$159,900.00876,756View SEC Filing  
9/15/2015Craig W MooreDirectorSell1,000$16.00$16,000.0097,046View SEC Filing  
9/14/2015Winifred L. SwanSVPSell2,500$16.01$40,025.0019,959View SEC Filing  
9/9/2015Joseph E. Turk, Jr.PresidentSell2,839$16.54$46,957.06107,663View SEC Filing  
8/25/2015Joseph E Turk JrPresidentSell2,000$18.25$36,500.00109,163View SEC Filing  
8/17/2015Robert S BrownInsiderSell10,825$18.30$198,097.50View SEC Filing  
8/14/2015Winifred L SwanSVPSell2,500$18.14$45,350.00View SEC Filing  
8/13/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
8/12/2015Jeffrey H BurbankCEOSell10,000$18.03$180,300.00View SEC Filing  
8/12/2015Joseph E Turk JrPresidentSell3,252$17.74$57,690.48View SEC Filing  
7/22/2015Joseph E Turk JrPresidentSell2,000$13.86$27,720.00View SEC Filing  
7/14/2015Winifred L SwanSVPSell2,500$14.71$36,775.00View SEC Filing  
6/23/2015Joseph E Turk JrPresidentSell2,000$15.36$30,720.00View SEC Filing  
6/18/2015Jeffrey H BurbankCEOSell20,000$15.56$311,200.00View SEC Filing  
6/15/2015Winifred L SwanSVPSell2,500$15.48$38,700.00View SEC Filing  
6/10/2015Joseph E Turk JrPresidentSell2,839$16.00$45,424.00View SEC Filing  
5/18/2015Winifred L SwanSVPSell2,500$16.65$41,625.00View SEC Filing  
5/12/2015Jeffrey H BurbankCEOSell10,000$16.44$164,400.00View SEC Filing  
4/21/2015Joseph E Turk JrPresidentSell1,950$18.40$35,880.00View SEC Filing  
4/17/2015Jeffrey H BurbankCEOSell10,000$18.08$180,800.00View SEC Filing  
4/16/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
4/8/2015Joseph E Turk JrPresidentSell1,500$18.34$27,510.00View SEC Filing  
3/26/2015Joseph E Turk JrPresidentSell1,150$16.94$19,481.00View SEC Filing  
3/18/2015Jeffrey H BurbankCEOSell20,000$17.40$348,000.00View SEC Filing  
3/10/2015Joseph E Turk JrPresidentSell1,500$16.44$24,660.00View SEC Filing  
2/25/2015Joseph E Turk JrPresidentSell2,082$17.88$37,226.16View SEC Filing  
1/27/2015Joseph E Turk JrPresidentSell2,350$18.70$43,945.00View SEC Filing  
1/14/2015Winifred L SwanSVPSell500$18.44$9,220.00View SEC Filing  
1/13/2015Joseph E Turk JrPresidentSell1,500$18.35$27,525.00View SEC Filing  
1/13/2015Winifred L SwanSVPSell666$18.35$12,221.10View SEC Filing  
12/29/2014Winifred L SwanSVPSell667$18.17$12,119.39View SEC Filing  
12/23/2014Joseph E Turk JrPresidentSell2,350$18.44$43,334.00View SEC Filing  
12/15/2014Joseph E Turk JrPresidentSell2,000$17.45$34,900.00View SEC Filing  
12/15/2014Kevin HershbergerCAOSell8,000$17.19$137,520.00View SEC Filing  
12/10/2014Joseph E Turk JrPresidentSell1,500$17.77$26,655.00View SEC Filing  
12/5/2014Jeffrey H BurbankCEOSell5,000$17.16$85,800.00View SEC Filing  
12/2/2014Robert S BrownInsiderSell34,700$17.44$605,168.00View SEC Filing  
12/1/2014Joseph E Turk JrPresidentSell24,762$17.04$421,944.48View SEC Filing  
12/1/2014Winifred L SwanSVPSell16,667$17.04$284,005.68View SEC Filing  
11/25/2014Joseph E Turk JrPresidentSell3,350$17.59$58,926.50View SEC Filing  
11/14/2014Joseph E Turk JrPresidentSell29,560$17.39$514,048.40View SEC Filing  
11/14/2014Winifred L SwanSVPSell17,167$17.37$298,190.79View SEC Filing  
11/12/2014Joseph E Turk JrPresidentSell26,261$16.27$427,266.47View SEC Filing  
11/12/2014Kevin HershbergerCAOSell11,056$16.58$183,308.48View SEC Filing  
11/7/2014Joseph E Turk JrPresidentSell24,761$16.25$402,366.25View SEC Filing  
11/3/2014Joseph E Turk JrPresidentSell5,717$15.50$88,613.50View SEC Filing  
10/23/2014Joseph E Turk JrPresidentSell3,550$14.55$51,652.50View SEC Filing  
10/23/2014Robert S BrownInsiderSell45,370$14.53$659,226.10View SEC Filing  
9/24/2014Joseph E Turk JrPresidentSell3,550$13.34$47,357.00View SEC Filing  
9/19/2014Jeffrey H BurbankCEOSell2,416$14.00$33,824.00View SEC Filing  
9/19/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
9/10/2014Kevin HershbergerCAOSell843$13.58$11,447.94View SEC Filing  
9/8/2014Jeffrey H BurbankCEOSell2,322$14.00$32,508.00View SEC Filing  
9/8/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
8/27/2014Joseph E Turk JrPresidentSell2,550$13.06$33,303.00View SEC Filing  
8/15/2014Winifred L SwanSVPSell2,500$13.60$34,000.00View SEC Filing  
8/7/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
8/7/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
7/24/2014Joseph E Turk JrPresidentSell3,550$13.50$47,925.00View SEC Filing  
7/18/2014Winifred L SwanSVPSell2,000$13.46$26,920.00View SEC Filing  
6/24/2014Joseph E Turk JrPresidentSell3,950$14.43$56,998.50View SEC Filing  
6/20/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/17/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/9/2014Winifred L SwanSVPSell9,228$14.00$129,192.00View SEC Filing  
6/5/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/5/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/5/2014Winifred L SwanSVPSell7,500$14.00$105,000.00View SEC Filing  
5/29/2014Joseph E Turk JrPresidentSell4,035$13.60$54,876.00View SEC Filing  
5/15/2014Winifred SwanSVPSell9,629$12.80$123,251.2021,688View SEC Filing  
5/14/2014Winifred SwanSVPSell5,000$13.04$65,200.0021,688View SEC Filing  
3/6/2014Robert FunariDirectorBuy10,150$14.72$149,408.0010,150View SEC Filing  
10/21/2013Robert S BrownInsiderSell140,100$14.00$1,961,400.00View SEC Filing  
9/9/2013Thomas SheaSVPSell1,000$12.30$12,300.00View SEC Filing  
8/12/2013Thomas SheaSVPSell1,172$12.93$15,153.9611,899View SEC Filing  
7/8/2013Thomas SheaSVPSell7,000$14.34$100,380.00View SEC Filing  
6/10/2013Thomas SheaSVPSell5,000$13.73$68,650.00View SEC Filing  
5/13/2013Thomas SheaSVPSell15,724$12.67$199,223.08View SEC Filing  
11/13/2012David S UtterbergDirectorSell184,204$11.58$2,133,082.32View SEC Filing  
11/2/2012David S UtterbergDirectorSell34,730$11.13$386,544.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NxStage (NASDAQ NXTM) News Headlines

Source:
DateHeadline
Critical Review: NxStage (NXTM) & Its CompetitorsCritical Review: NxStage (NXTM) & Its Competitors
www.americanbankingnews.com - April 15 at 3:11 AM
NxStage (NXTM) Downgraded to "Sell" at BidaskClubNxStage (NXTM) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
Medisystems Announces US Release of MasterGuard® PlusMedisystems Announces US Release of MasterGuard® Plus
finance.yahoo.com - April 13 at 8:58 AM
Jefferies Group Lowers NxStage (NXTM) to HoldJefferies Group Lowers NxStage (NXTM) to Hold
www.americanbankingnews.com - April 12 at 9:00 PM
NxStage (NXTM) Given Average Recommendation of "Hold" by BrokeragesNxStage (NXTM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 12 at 5:45 PM
Zacks Investment Research Upgrades NxStage (NXTM) to BuyZacks Investment Research Upgrades NxStage (NXTM) to Buy
www.americanbankingnews.com - April 11 at 5:35 PM
Zacks Investment Research Downgrades NxStage (NXTM) to HoldZacks Investment Research Downgrades NxStage (NXTM) to Hold
www.americanbankingnews.com - April 10 at 7:17 PM
Leerink Swann Downgrades NxStage (NXTM) to Market PerformLeerink Swann Downgrades NxStage (NXTM) to Market Perform
www.americanbankingnews.com - April 9 at 11:27 PM
NxStage (NXTM) Upgraded at ValuEngineNxStage (NXTM) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 11:04 AM
NxStage Medical (NXTM) Lifted to "Hold" at Zacks Investment ResearchNxStage Medical (NXTM) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 12:58 PM
NxStage Medical (NXTM) Lifted to Sell at BidaskClubNxStage Medical (NXTM) Lifted to Sell at BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM
NxStage Medical (NXTM) Upgraded by BidaskClub to "Sell"NxStage Medical (NXTM) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 24 at 6:46 PM
Comparing NxStage Medical (NXTM) & The CompetitionComparing NxStage Medical (NXTM) & The Competition
www.americanbankingnews.com - March 24 at 3:21 AM
NxStage Medical, Inc. (NXTM) Given Average Rating of "Hold" by AnalystsNxStage Medical, Inc. (NXTM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 18 at 5:34 PM
NxStage Celebrates Fifth Annual National Home Hemodialysis DayNxStage Celebrates Fifth Annual National Home Hemodialysis Day
finance.yahoo.com - March 15 at 8:43 AM
Seven Unique NxStage Abstracts Presented During the 38th Annual ... - PR Newswire (press release)Seven Unique NxStage Abstracts Presented During the 38th Annual ... - PR Newswire (press release)
www.prnewswire.com - March 14 at 9:19 AM
NxStage Medical (NXTM) Downgraded to "Sell" at Zacks Investment ResearchNxStage Medical (NXTM) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 11 at 1:17 PM
275,000 Shares in NxStage Medical, Inc. (NXTM) Acquired by Tamarack Advisers LP275,000 Shares in NxStage Medical, Inc. (NXTM) Acquired by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:30 AM
Recent Analysis Shows ILG, Diamond Offshore Drilling, Interactive Brokers Group, NxStage Medical, Broadridge Financial Solutions, and ServiceNow Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows ILG, Diamond Offshore Drilling, Interactive Brokers Group, NxStage Medical, Broadridge Financial Solutions, and ServiceNow Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - March 6 at 8:42 AM
Senzar Asset Management LLC Buys New Stake in NxStage Medical, Inc. (NXTM)Senzar Asset Management LLC Buys New Stake in NxStage Medical, Inc. (NXTM)
www.americanbankingnews.com - March 5 at 3:44 PM
NxStage Medical, Inc. (NXTM) Position Lifted by Koch Industries Inc.NxStage Medical, Inc. (NXTM) Position Lifted by Koch Industries Inc.
www.americanbankingnews.com - March 5 at 3:06 PM
Water Island Capital LLC Has $19.48 Million Position in NxStage Medical, Inc. (NXTM)Water Island Capital LLC Has $19.48 Million Position in NxStage Medical, Inc. (NXTM)
www.americanbankingnews.com - March 2 at 9:38 PM
Zacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Post Quarterly Sales of $104.45 MillionZacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Post Quarterly Sales of $104.45 Million
www.americanbankingnews.com - March 2 at 2:44 AM
Yakira Capital Management Inc. Acquires 35,000 Shares of NxStage Medical, Inc. (NXTM)Yakira Capital Management Inc. Acquires 35,000 Shares of NxStage Medical, Inc. (NXTM)
www.americanbankingnews.com - February 28 at 5:04 PM
Fresenius 4Q net profit rises on hospital segmentFresenius 4Q net profit rises on hospital segment
www.marketwatch.com - February 27 at 8:48 AM
What Analysts Recommend for Abiomed and Peers in February 2018What Analysts Recommend for Abiomed and Peers in February 2018
finance.yahoo.com - February 27 at 8:48 AM
Why Abiomed’s Product Pipeline Looks PromisingWhy Abiomed’s Product Pipeline Looks Promising
finance.yahoo.com - February 27 at 8:48 AM
NxStage Medical, Inc. (NXTM) Shares Bought by Dumac Inc.NxStage Medical, Inc. (NXTM) Shares Bought by Dumac Inc.
www.americanbankingnews.com - February 26 at 3:36 PM
K2 Principal Fund L.P. Purchases New Holdings in NxStage Medical, Inc. (NXTM)K2 Principal Fund L.P. Purchases New Holdings in NxStage Medical, Inc. (NXTM)
www.americanbankingnews.com - February 26 at 3:12 PM
Wider Losses Worry NxStage Medical ShareholdersWider Losses Worry NxStage Medical Shareholders
www.fool.com - February 26 at 11:35 AM
NxStage Medical, Inc. (NXTM) SVP Sells $85,680.00 in StockNxStage Medical, Inc. (NXTM) SVP Sells $85,680.00 in Stock
www.americanbankingnews.com - February 22 at 7:08 PM
A Look at NxStage Medical’s Business StrategyA Look at NxStage Medical’s Business Strategy
finance.yahoo.com - February 22 at 5:19 PM
NxStage Medical, Inc. (NXTM) Receives Consensus Rating of "Hold" from AnalystsNxStage Medical, Inc. (NXTM) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 5:34 PM
NxStage Medical (NXTM) Stock Rating Lowered by BidaskClubNxStage Medical (NXTM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 17 at 10:28 PM
NxStage Medical (NXTM) Rating Lowered to Sell at Zacks Investment ResearchNxStage Medical (NXTM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 13 at 6:30 AM
$104.45 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$104.45 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - February 13 at 1:02 AM
ValuEngine Downgrades NxStage Medical (NXTM) to SellValuEngine Downgrades NxStage Medical (NXTM) to Sell
www.americanbankingnews.com - February 4 at 7:12 PM
Zacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $104.80 MillionZacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $104.80 Million
www.americanbankingnews.com - January 28 at 6:58 AM
NxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from AnalystsNxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 5:34 PM
NxStage Medical (NXTM) Upgraded by Zacks Investment Research to "Hold"NxStage Medical (NXTM) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 26 at 6:08 AM
Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) StockWinifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock
www.americanbankingnews.com - January 19 at 10:26 PM
This Mornings Technical Outlook on Medical Equipment Stocks -- Nxstage Medical, Nevro, Prestige Brands, and Varian Medical SystemsThis Morning's Technical Outlook on Medical Equipment Stocks -- Nxstage Medical, Nevro, Prestige Brands, and Varian Medical Systems
www.prnewswire.com - January 17 at 10:06 AM
$104.80 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$104.80 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - January 10 at 2:42 AM
NxStage Medical (NXTM) Stock Rating Upgraded by Zacks Investment ResearchNxStage Medical (NXTM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 3 at 2:42 PM
NxStage Medical, Inc. (NXTM) Short Interest UpdateNxStage Medical, Inc. (NXTM) Short Interest Update
www.americanbankingnews.com - December 31 at 4:22 AM
ETFs with exposure to NxStage Medical, Inc. : December 26, 2017ETFs with exposure to NxStage Medical, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 2:38 PM
NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:16 PM
Zacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 MillionZacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - December 25 at 2:26 PM
NxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.01 Per ShareNxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - December 23 at 1:10 PM
NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 SharesNxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares
www.americanbankingnews.com - December 21 at 5:52 PM

SEC Filings

NxStage (NASDAQ:NXTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NxStage (NASDAQ:NXTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NxStage (NASDAQ NXTM) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.